Switch to Dolutegravir-Abacavir-Lamivudine

STRIIVING Study
Switch to Dolutegravir-Abacavir-Lamivudine (DTG-ABC-3TC) STRIIVING: Design

**Study Design: STRIIVING**

- **Background**: Open-label, randomized study, phase 3 trial comparing switch to dolutegravir-abacavir-lamivudine (DTG-ABC-3TC) versus continuation of baseline ART

- **Inclusion Criteria** (n = 553)
  - HIV RNA <50 copies/mL on ART
  - Stable on current ART for ≥6 months
  - No prior virologic failure
  - HLA B5701 negative

- **Treatment Arms**
  - Switch to DTG-ABC-3TC
  - Continuation of Baseline ART x 24 weeks, then switch to DTG-ABC-3TC

*Baseline antiretroviral therapy (ART) consisting of 2 NRTIs + Anchor drug (NNRTI, PI, or INSTI)*

**Week 0**

- Early Switch Group
  - DTG-ABC-3TC (n = 275)

**Week 24**

- Late Switch Group
  - Baseline ART (n = 278)

**Week 48**

- Late Switch Group
  - DTG-ABC-3TC (n = 244)

Switch to Dolutegravir-Abacavir-Lamivudine (DTG-ABC-3TC)

STRIIVING: Results

Week 24 and 48 Virologic Response

<table>
<thead>
<tr>
<th></th>
<th>Week 24</th>
<th></th>
<th>Week 48</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HIV RNA &lt;50 copies/mL (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early Switch Group</td>
<td>234/275</td>
<td>245/278</td>
<td>228/275</td>
<td>224/244</td>
</tr>
<tr>
<td>Late Switch Group</td>
<td>85</td>
<td>88</td>
<td>83</td>
<td>92</td>
</tr>
</tbody>
</table>

Switch to Dolutegravir-Abacavir-Lamivudine (DTG-ABC-3TC)

STRIIVING: Conclusions

**Conclusions**: “Data demonstrating non-inferiority of switching to ABC/DTG/3TC versus continuing current ART support ABC/DTG/3TC as an option when considering switch regimens in HIV-1-infected adults with stable viral suppression.”

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.